References
- Staples M, Daniel K, Cima MJ, Langer R. Application of micro- and nano-electromechanical devices to drug delivery. Pharm. Res. 23(5), 847–863 (2006).
- Arora A, Prausnitz MR, Mitragotri S. Micro-scale devices for transdermal drug delivery. Int. J. Pharm. 364(2), 227–236 (2008).
- Santini JT Jr, Cima MJ, Langer R. A controlled-release microchip. Nature 397(6717), 335–338 (1999).
- Farra R, Sheppard NF Jr, McCabe L et al. First-in-human testing of a wirelessly controlled drug delivery microchip. Sci. Transl. Med. 4(122), 122ra21 (2012).
- Glover SJ, Eastell R, McCloskey EV et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 45(6), 1053–1058 (2009).
- Sieg A, Wascotte V. Diagnostic and therapeutic applications of iontophoresis. J. Drug Target 17(9), 690–700 (2009).
- Kreyden OP. Iontophoresis for palmoplantar hyperhidrosis. J. Cosmet. Dermatol. 3(4), 211–214 (2004).
- Beauchamp M, Lands LC. Sweat-testing: a review of current technical requirements. Pediatr. Pulmonol. 39(6), 507–511 (2005).
- Mayes S, Ferrone M. Fentanyl HCl patient-controlled iontophoretic transdermal system for the management of acute postoperative pain. Ann. Pharmacother. 40(12), 2178–2186 (2006).
- Schaepelynck P, Darmon P, Molines L, Jannot-Lamotte MF, Treglia C, Raccah D. Advances in pump technology: insulin patch pumps, combined pumps and glucose sensors, and implanted pumps. Diabetes Metab. 37(Suppl. 4), S85–S93 (2011).
- Welchew E. Patient Controlled Analgesia: Principles and Practice Series. BMJ Publishing Group, London, UK (2011).
- Penn RD, Savoy SM, Corcos D et al. Intrathecal baclofen for severe spinal spasticity. N. Engl. J. Med. 320(23), 1517–1521 (1989).
- Koulousakis A, Kuchta J, Bayarassou A, Sturm V. Intrathecal opioids for intractable pain syndromes. Acta Neurochir. Suppl. 97(Pt 1), 43–48 (2007).
Website
- Ahn HY. Clinical Pharmacology and Biopharmaceutics Review. (FDA, Center for Drug Evaluation and Research, Silver Spring, MD, USA, 2002). www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21–318_FORTEO_BioPharmr.pdf (Accessed 17 April 2012)